Protagonist Therapeutics, Inc.
PTGX
Rangering i aksjer
#2299
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to... Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Aksjekurs
$134.37
Markedsverdi
$8.70B
Endring (1 dag)
4.37%
Endring (1 år)
73.38%
Land
US
Handel Protagonist Therapeutics, Inc. (PTGX)
Kategori
Healthcare
Driftsmargin for Protagonist Therapeutics, Inc. (PTGX)
Driftsmargin per October 2026 TTM: 20.69%
Ifølge Protagonist Therapeutics, Inc. sine siste økonomiske rapporter og aksjekurs er selskapets nåværende driftsmargin (TTM) 20.69%. Ved slutten av 2023 hadde selskapet en driftsmargin på -156.09%.
Historikk for driftsmargin for Protagonist Therapeutics, Inc. fra 2014 til 2026
Driftsmargin ved slutten av hvert år
| År | Driftsmargin | Endre |
|---|---|---|
| 2026 (TTM) | 20.69% | -64.45% |
| 2024 | 58.20% | -137.29% |
| 2023 | -156.09% | -68.42% |
| 2022 | -494.24% | 7.44% |
| 2021 | -460.01% | 104.12% |
| 2020 | -225.36% | -99.35% |
| 2019 | -34,857.58% | 25,403.06% |
| 2018 | -136.68% | -27.64% |
| 2017 | -188.89% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
Driftsmargin for lignende selskaper eller konkurrenter
| Selskap | Driftsmargin | Forskjell i driftsmargin | Land |
|---|---|---|---|
| 38.59% | -98.13% |
US
|
|
| -149.01% | -107.20% |
US
|
|
| 25.57% | -98.76% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -98.61% |
NL
|
Hva er selskapets Driftsmargin?
Driftsmargin er en nøkkelindikator for å vurdere lønnsomheten til et selskap. Høyere Driftsmargins er vanligvis bedre, da de viser at selskapet kan selge sine produkter eller tjenester for mye mer enn produksjonskostnadene. Driftsmargin beregnes ved å dele selskapets inntjening med inntektene.